Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | TXN | P10599 | 1/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2921587 | 0.83 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2TAAR1TXNTXNRD1 | |
| SCHEMBL18238088 | 0.74 | PARP1 (0.43) | ALDH1A1RAB9AHPGDLMNAHSD17B10 | |
| SCHEMBL7878663 | 0.73 | NISCH (0.43) | SMN1; SMN2CAPN1TAAR1ADRA2AADRA2B | |
| SCHEMBL723777 | 0.70 | — | — | |
| SCHEMBL3986519 | 0.69 | PDE3B (0.45) | ALDH1A1SMN1; SMN2TAAR1TXNTXNRD1 | |
| SCHEMBL6647148 | 0.69 | JAK2 (0.40) | ALDH1A1SMN1; SMN2TXNTXNRD1FDPS | |
| Hydrochloric Acid SCHEMBL7393663 | 0.68 | — | — | |
| SCHEMBL29059442 | 0.67 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2TXNTXNRD1NISCH | |
| SCHEMBL189942 | 0.67 | — | — | |
| SCHEMBL2732228 | 0.67 | PIK3CG (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023205468-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | ARRAY BIOPHARMA INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-116462635-A | Pyrazine-1 (2H) -2-oxo compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-05-05 | — | — | US | disclosed |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | GILEAD SCIENCES, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200138812-A1 | LIVER X RECEPTOR MODULATORS | VITAE PHARMACEUTICALS LLC (US) | 2020-05-07 | — | — | US | disclosed |
| US-8163787-B2 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2011144622-A1 | 1H - IMIDAZO [4, 5 - C] QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011131741-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDES AS PDK1 INIHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | WO | disclosed |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2011-05-12 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-7807690-B2 | 2,3-dihydro-iminoisoindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2010-07-29 | — | — | US | disclosed |
| US-20100184981-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | CLARK RICHARD | 2010-07-22 | — | — | US | disclosed |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184981-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | SERPINC1, F7, F2 | ALDH1A1 1133/4885SMN1; SMN2 3093/4885CAPN1 2125/4885 |
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | H1-0, H1-10, H1-2 | ALDH1A1 701/4885SMN1; SMN2 3953/4885CAPN1 3681/4885 |
| US-20200163953-A1 | Compounds for Inhibition of Alpha 4 Beta 7 Integrin | ITGB7, ITGB4, ITGA4 | ALDH1A1 823/4885SMN1; SMN2 1977/4885CAPN1 1812/4885 |
| US-20230011441-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | ALDH1A1 2121/4885SMN1; SMN2 3166/4885CAPN1 1874/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | ALDH1A1 2230/4885SMN1; SMN2 716/4885CAPN1 1211/4885 |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | H1-10, H1-0, H1-2 | ALDH1A1 905/4885SMN1; SMN2 4234/4885CAPN1 3624/4885 |
| US-20200138812-A1 | LIVER X RECEPTOR MODULATORS | SLC10A1, NR1H4, NR1H2 | ALDH1A1 882/4885SMN1; SMN2 3358/4885CAPN1 3627/4885 |
| US-11179383-B2 | Compounds for inhibition of α4β7 integrin | ITGB7, ITGB4, ITGA4 | ALDH1A1 791/4885SMN1; SMN2 2200/4885CAPN1 2416/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | ALDH1A1 2230/4885SMN1; SMN2 716/4885CAPN1 1211/4885 |
| US-20090270433-A1 | 2,3-DIHYDRO-IMINOISOINDOLE DERIVATIVES | SERPINC1, F7, F2 | ALDH1A1 1107/4885SMN1; SMN2 3269/4885CAPN1 2148/4885 |
| US-20220135561-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | ALDH1A1 193/4885SMN1; SMN2 423/4885CAPN1 4106/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | ALDH1A1 710/4885SMN1; SMN2 3935/4885CAPN1 3910/4885 |
| US-11780835-B2 | Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases | RET, MERTK, MET | ALDH1A1 2121/4885SMN1; SMN2 3166/4885CAPN1 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.